Endocrine connections 2017 11 30() pii EC-17-0276
Chromogranin-A (CgA) and neuron-specific enolase (NSE) are important markers for neuroendocrine tumors, however, the clinical value of combining these markers has not been well studied. In this study we investigated the utility of each marker individually and in combination for patients with nonfunctional pancreatic neuroendocrine tumors (NF-pNETs).
PATIENTS AND METHODS
In this study, NF-pNETs patients and controls were recruited from December 2011 to March 2016; 784 serum samples from peripheral vein were collected. The clinical characteristics, biomarker value of all the individuals were recorded and analyzed. Tumor burdens were calculated by CT/MRI scan. Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic predictive value, sensitivity and specificity were calculated to determine the cut-off value. Therapeutic response reflected on the changes of the biomarkers’ levels were assessed by RECIST criterion. Clinical relation between the prognosis and biomarkers values were also analyzed. Statistical significance was defined as P value less than 0.05.
Among the 167 NF-pNETs patients, 82 were males (49.10%) and the mean age was 50.0 (17.4). The mean CgA values of G1, G2 and G3 NF-pNENs were 75μg/l, 121μg/l and 134μg/l (P<0.05). In NF-pNETs, CgA correlated with the WHO tumor grade (WHO G1 versus G2, P<0.05); the linear regression relationships were found between the tumor burdens (both in pancreas and liver) and CgA levels (P<0.001); changes in CgA and NSE levels also reflect treatment response (P<0.001). CONCLUSION
CgA and NSE are important diagnostic and follow-up markers in patients with NF-pNETs. The combined monitor of CgA and NSE possess more accuracy than individual value of CgA and NSE at predicting prognosis and disease progression.